The purpose of this study is to estimate overall survival for adult patients with newly diagnosed glioblastoma multiforme treated with talampanel during radiation therapy with concurrent and adjuvant temozolomide. This study will also determine the toxicity and toxicity rate of talampanel for this therapeutic regimen.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
72
Talampanel administered orally TID beginning the first day and continued until there is talampanel-related toxicity or tumor progression.
temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks
Overall Survival
Time frame: 24 months
Talampanel-related toxicity
Time frame: 29 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months.